Fighting for victims of Spinal Cord Injuries
Email this page to a friend Print this page

WWW.FINZFIRM.COM
1-888-FINZFIRM
1-888-346-9347
Finz & Finz, P.C.
Attorneys And Counselors At Law

FDA puts Geron spinal cord injury drug on hold

May 16, 2008 | Staff | Forbes News

Biopharmaceutical company Geron Corp. said Wednesday the Food and Drug Administration has placed a clinical hold on its experimental cell therapy for spinal cord injury, GRNOPC1.

A clinical hold is an order that the FDA issues to delay a proposed trial or suspend an ongoing investigation.

"We have not yet received a letter from the FDA explaining the decision to place the submission on hold, so we are unable to comment specifically," said Thomas Okarma, Gerons president and chief executive. "Once we have the letter and have had a discussion with the agency, we will communicate our findings and our thinking to shareholders."

The company said it is "disappointed" given that the submission has been in development for four years and has been predicated on discussions with regulators.

MORE SPINAL CORD INJURY NEWS...

(required) Denotes required field

Title


(required) First Name


(required) Last Name


(required) Email Address


(required) Phone Number


Address


City


(required) State


Zip Code


Best Way/Time to Contact You


Injured Person's Name


Injured Person's Date of Birth
(mm/dd/yyyy)

Date of Incident
(mm/dd/yyyy)

Type of Incident


Please Describe the Incident


Please sign me up for the Finz & Finz, P.C. Newsletter


I agree to the Finz & Finz, P.C. Terms of Use